Elsevier,
Lancet Regional Health - Americas, Volume 20, April 2023
This Viewpoint supports Sustainable Development Goal 3 by discussing the effects of the FDA's approval of aducanumab, a treatment for early-stage Alzheimer's disease, despite its limited clinical benefit, as well as the decision of the Centers for Medicare and Medicaid Services to restrict coverage to individuals enrolled in clinical trials. The authors note that these decisions have led to a confusing landscape for patients with Alzheimer's disease.
Elsevier,
Environment International, Volume 174, April 2023
The current review on atmospheric M/NPs is therefore focusing on sampling, sample preparation and identification methods. The approach will enable knowledge gaps to be identified, and recommendations to be made to support standardized and comparable future research
Elsevier,
Current Opinion in Green and Sustainable Chemistry, Volume 40, April 2023
This review artcile, with contributionsform allover the world, describes various approaches to convert plastic wastes into new products known as an efficient way to manage them and to enhance the sustainability of the environment.
Elsevier,
Energy and AI, Volume 12, April 2023
This article supports SDGs 7 and 13 by achieving the efficient CO2 capture via connecting a packed bubble column (S-PBC) contactor in series, combined with machine learning and multi-objective optimization based on Enhanced Weathering (EW) technology.
Elsevier,
Trends in Immunology, Volume 44, April 2023
Human immunodeficiency virus and Simian immunodeficiency (SIV) are highly immune evasive viruses with few vulnerabilities. Cytomegalovirus vector-programmed MHC-E-restricted CD8+ T cells can mediate complete replication arrest of primary SIV infection with subsequent viral clearance; this approach may be promising for putative vaccines or immuno-therapeutics against HIV.
Elsevier,
eClinicalMedicine, Volume 58, April 2023
TB is often reported in people with HIV, in whom isoniazid preventive therapy (IPT) is a treamtent regimen used to prevent TB infection. However, when mothers with HIV recieived IPT during their pregnancy, their babies were associated with an increased risk low birth weight, preterm birth, and becoming under weight. Males seemed to be particularly effected. This brings into question the use of IPT in pregnant women with HIV as the health-care communitry seeks to reach SDGs 3.1, 3.2, and 3.3.